Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Enterprise Integration Has Not Yet Advanced among Drugmakers in Japan: Former JFTC Chairman Takeshima
September 27, 2012
- MHLW to Announce 14 New Examples of Approved Off-Label Drug Use Based on 1980 Notification in Near Future
September 26, 2012
- Risk for 7 Main Diseases Increases at Age 63: Anti-Aging Laboratory
September 25, 2012
- JPA Issues Notice on Prohibition of Dispensing Point Services, “Not Intended as Transitional Measure”
September 25, 2012
- Wholesale Industry FTC’s Liaison Conference on Ending Provision of Free Benefits and Labor to Hold 1st Meeting in October
September 25, 2012
- MHLW Reports Results of Analysis of “Close-Call” Incidents at Pharmacies with Generics
September 24, 2012
- Mr Hayashi of OPIR Stresses Need for Approval and Reimbursement of More Companion Diagnostics
September 21, 2012
- Dr Fukuda Lays Out 4 Options for HTA Introduction in Drug Pricing
September 20, 2012
- Anti-Japanese Demonstrations in China Have Had “Absolutely No Effect” on Takeda: President Hasegawa
September 20, 2012
- Maker FTC Bans Drink Donations at Academic Conferences
September 19, 2012
- Iyakuhin Renmei to Break Up to Create Unified Pharmaceutical Industry Labor Union
September 14, 2012
- 35% of Domestic Drug Makers Do Not Conduct First-in-Human Trials in Japan: JPMA Survey
September 5, 2012
- Dr Teshirogi of JPMA Comments on Govt’s Efforts to Promote Regulatory Science; Expresses Concerns About Japan’s Future as Drug-Originating Country
September 5, 2012
- Total Number of MRs Up 4.3% at 63,875, Marking Largest Number in History: MR White Paper
September 5, 2012
- JGA Fails to Achieve Goal of Eliminating “Out-of-Stock” Products Yet Again
August 31, 2012
- Generic Market Share at 25.3% in April-June; Marks Largest Increase: JGA
August 28, 2012
- MHLW Must Present Thorough Explanation If It Insists on Lawmaker-Initiated Bill to Establish 3rd-Party Organization: Yakuhiren
August 28, 2012
- AJD Prioritize Brand Unification of Generic Drugs
August 27, 2012
- Wholesaler’s Operating Profit Margin Improves to 0.31%, Yet Far Cry from FY2007 Level: JPWA
August 10, 2012
- PI Forum to Make Proposals to Promote R&D, Make Pharmaceuticals Japan’s Key Industry: Chairman Toyoda
August 9, 2012
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…